New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
08:00 EDTAEGRAegerion subpoena not a 'major surprise,' says Leerink
Leerink views the Aegerion's subpoena from the U.S. Department of Justice as not a "major surprise" after the FDA reprimanded the company for statements made by its CEO on CNBC that suggested Juxtapid can improve patient survival, which has not been studied in clinical trial. The firm expects the subpoena will result in more rigorous marketing practices controlled by compliance and a “manageable fine" and reiterates an Outperform rating on Aegerion.
News For AEGR From The Last 14 Days
Check below for free stories on AEGR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
08:08 EDTAEGRAegerion initiates Phase 3 clinical trial for lomitapide in Japan
Subscribe for More Information
April 8, 2014
11:03 EDTAEGRPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use